Helio Genomics will present three abstracts at the 2025 Digestive Disease Week in San Diego — including the first showcase of a simulated longitudinal study comparing HelioLiver against ultrasound for HCC detection in cirrhosis.
IRVINE, Calif., May 6, 2025 /PRNewswire/ — Helio Genomics (“Helio” or “the Company”) today showcased results from three cancer detection studies at the 2025 Digestive Disease Week (DDW) Conference, held at the San Diego Convention Center from May 4–6, 2025 — most notably the first showcase of a simulated longitudinal study comparing a multi-analyte blood-based test (HelioLiver Dx) against ultrasound for detecting hepatocellular carcinoma (HCC) in patients with cirrhosis.
Key Findings from Poster #1
Simulation of Longitudinal Ultrasound versus a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma in Patients with Cirrhosis (4254801), presented by Dr. Amit Singal, MD, MS, FAASLD, Professor of Medicine, UT Southwestern Medical Center.
- The study used a Monte Carlo simulation to model HelioLiver Dx sensitivities for detecting HCC at multiple time points of routine surveillance.
- In the base case (assuming a tumor doubling time of 6 months), HelioLiver Dx had sensitivities for any-stage HCC of 77.2%, 97.6% and 100% at 6, 12 and 18 months, respectively. Sensitivities for early-stage HCC were 58.7%, 61.2% and 61.2% at 6, 12 and 18 months.
- In a sensitivity analysis assuming differential growth patterns (including indolent and aggressive tumor biology), sensitivities for early-stage HCC were similar — 54.7%, 59.4% and 60.8% at 6, 12 and 18 months.
- The results reinforce that a blood-based test such as HelioLiver Dx detects a high proportion of patients at an early stage.
“This simulation study demonstrates that a multi-analyte blood-based test is a promising strategy that may improve early-stage hepatocellular carcinoma detection compared to ultrasound, particularly for finding tumors at a small size, when curative therapies would be available.”
Helio also reiterated results on the utility of methylation models for evaluating prognosis and treatment response, as well as clinical trial data from CLiMB — the largest completed multi-center prospective trial for a liver cancer detection liquid biopsy test.
- Poster #2: Cell-Free DNA Methylation Biomarkers for Evaluating Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma (4254671) — presented by Shivani Mahajan, Ph.D., Head of Computational Science at Helio Genomics.
- Poster #3: CLiMB: A Prospective, Blinded, Multicenter U.S.-Based Study Evaluating a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma (HCC) in Patients with Liver Cirrhosis (4253880) — presented by Dr. Richard Van Etten, Director of the Chao Family Comprehensive Cancer Center at UCI and Chief Medical Advisor at Helio Genomics.
Copies of the poster presentations are available in the “Past Events” section on Helio’s website at heliogenomics.com/news-and-events.
About Helio Genomics
Helio Genomics is a commercial stage, AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection. HelioLiver is a multi-analyte blood test that evaluates cell free DNA (cfDNA) methylation patterns, serum protein markers, and demographic information for the detection of hepatocellular carcinoma (HCC).
SOURCE Helio Genomics. View source version on PR Newswire.